FDA Overreach? Treating your cells as drugs

In today's Wall Street Journal, American Enterprise Institute (AEI) resident fellow and former Food and Drug Administration (FDA) deputy commissioner Scott Gottlieb, MD explains that the FDA's attempt to regulate cells as drugs could halt one of the most promising areas of medical research.


Gottlieb explains:

  • FDA wants to regulate cells: "At issue are cells taken from our own bodies and then re-implanted with the purpose of treating medical problems. The most inspiring work involves adult stem cells, although the court's ruling in principle extends FDA oversight into things as common as in-vitro fertilization--basically turning reproductive cells into "drugs" under the law." Two weeks ago, a United States District Court ruled that adult stem cells are drugs, and thus subject to FDA regulation.
  • FDA regulations hamper unique procedures: "Doctors will now try to convert procedures into products that can fit FDA's regulatory rubric….Not every cell procedure will lend itself to this sort of revision. How, for instance, would you run a large-scale, randomized trial and ensure consistency from one use of a drug to another, where the "drug" is really a medical procedure that must vary from one patient to the next because it involves their own unique cells?"
  • Pushing innovation outside of the Untied States: The company involved in the court case, Regenerative Sciences, has moved some labs to the Cayman Islands. Most of the adult stem cell science research is being done in Britain, Singapore, and Israel "precisely because of the FDA's bent to hold with misgiving anything novel in medicine."



"The FDA is perennially complaining to Congress that it lacks the resources to do its day job of regulating products that fall squarely in its purview. Yet in chorus, the agency is always seeking novel authority to insert itself into new areas of science where its mandate is shaky…[this goal] can be deadly when it comes to the agency's impulse to regulate, and thus forestall, cell therapies used to help repair damaged body parts."


Scott Gottlieb is a practicing physician and resident fellow at the American Enterprise Institute. He was deputy commissioner of the FDA and a senior adviser at the Centers for Medicare and Medicaid Services. He can be reached at scott.gottlieb@aei.org.


For additional help, other media inquiries, or to reserve AEI's in-house TV studio or ISDN facilities, please contact:


TV Jesse Blumenthal jesse.blumenthal@aei.org / 202.862.4870


Radio Michael Pratt michael.pratt@aei.org / 202.862.5823


Print or Web Jesse Blumenthal jesse@aei.org / 202.862.4870, Michael Pratt at michael.pratt@aei.org / 202.862.5823, or Veronique Rodman at vrodman@aei.org / 202.862.4871


Follow @AEInews

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Scott
Gottlieb
  • Scott Gottlieb, M.D., a practicing physician, has served in various capacities at the Food and Drug Administration, including senior adviser for medical technology; director of medical policy development; and, most recently, deputy commissioner for medical and scientific affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare & Medicaid Services. 

    Click here to read Scott’s Medical Innovation blog.


    Follow Scott Gottlieb on Twitter.

  • Phone: 202.862.5885
    Email: scott.gottlieb@aei.org
  • Assistant Info

    Name: Kelly Funderburk
    Phone: 202.862.5920
    Email: Kelly.Funderburk@AEI.org

What's new on AEI

image The Census Bureau and Obamacare: Dumb decision? Yes. Conspiracy? No.
image A 'three-state solution' for Middle East peace
image Give the CBO long-range tools
image The coming collapse of India's communists
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled today.
No events scheduled this day.